| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $677K | — | — |
| SG&A Expense | $274K | +375.0% | +193.5% |
| Operating Income | -$951K | -1549.9% | -919.7% |
| Net Income | -$954K | -1481.0% | -946.5% |
| EPS (Basic) | -$0.04 | — | +0.0% |
| EPS (Diluted) | -$0.04 | — | +0.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.8M | — | — |
| Current Assets | $14.4M | +1926.9% | — |
| Total Assets | $14.5M | +1739.3% | — |
| Current Liabilities | $186K | +144.9% | — |
| Total Liabilities | $186K | -61.4% | — |
| Stockholders' Equity | $14.3M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.6M | — | — |
| Financing Cash Flow | $15.3M | — | — |
| +4579.4% |
| +2189.8% |